Operating
Stock-Based Comp
Moderna Stock-Based Comp decreased by 8.0% to $104.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 9.6%, from $115.00M to $104.00M. Over 4 years (FY 2021 to FY 2025), Stock-Based Comp shows an upward trend with a 35.8% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2016
Last reportedQ1 2026May 1, 2026
How to read this metric
Increasing levels may indicate a focus on talent retention but can also signal potential shareholder dilution.
Detailed definition
This represents the value of equity-based awards granted to employees as part of their total compensation package. Since...
Peer comparison
Standard across large-cap corporations; varies based on corporate compensation philosophy.
Metric ID:
stock_based_compensationHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $35.00M | $40.00M | $37.00M | $44.00M | $50.00M | $70.00M | $62.00M | $75.00M | $74.00M | $77.00M | $79.00M | $101.00M | $112.00M | $112.00M | $104.00M | $115.00M | $130.00M | $125.00M | $113.00M | $104.00M |
| QoQ Change | — | +14.3% | -7.5% | +18.9% | +13.6% | +40.0% | -11.4% | +21.0% | -1.3% | +4.1% | +2.6% | +27.8% | +10.9% | +0.0% | -7.1% | +10.6% | +13.0% | -3.8% | -9.6% | -8.0% |
| YoY Change | — | — | — | — | +42.9% | +75.0% | +67.6% | +70.5% | +48.0% | +10.0% | +27.4% | +34.7% | +51.4% | +45.5% | +31.6% | +13.9% | +16.1% | +11.6% | +8.7% | -9.6% |
Range$35.00M – $130.00M
CAGR+25.8%
Avg YoY Growth+34.1%
Median YoY Growth+33.2%
Current Streak3 quarters decline
Stock-Based Comp at Other Companies
Frequently Asked Questions
- What is Moderna's stock-based comp?
- Moderna (MRNA) reported stock-based comp of $104.00M in Q1 2026.
- How has Moderna's stock-based comp changed year-over-year?
- Moderna's stock-based comp decreased by 9.6% year-over-year, from $115.00M to $104.00M.
- What is the long-term trend for Moderna's stock-based comp?
- Over 4 years (2021 to 2025), Moderna's stock-based comp has grown at a 35.8% compound annual growth rate (CAGR), from $142.00M to $483.00M.
- What does stock-based comp mean?
- The non-cash cost of paying employees with company stock instead of cash.